Lysosomal Therapeutics
Latest round
- Series A
Last raised
- Jan 2017
Total raised
- $31M
Investors
- 8
About Lysosomal Therapeutics
Lysosomal Therapeutics, Inc.Founded in 2014 in Cambridge, US, Lysosomal Therapeutics, Inc. specializes in therapies for lysosomal storage disorders.00 mn.13 mn.Lysosomal Therapeutics, Inc. specializes in the development of innovative therapies aimed at addressing lysosomal storage disorders (LSDs). Their core product offerings include enzyme replacement therapies and substrate reduction therapies designed to enhance the quality of life for individuals affected by these genetic conditions. These therapies function by replenishing deficient enzymes or reducing the accumulation of toxic substrates within lysosomes, ultimately aiming to alleviate the symptoms associated with LSDs. The company targets a diverse client base, including healthcare providers, hospitals, and specialty pharmacies, serving patients primarily in North America and select European markets.The revenue model for Lysosomal Therapeutics is primarily structured around direct sales of its specialized therapeutic products to healthcare institutions and pharmacies. Transactions typically occur through negotiated contracts with hospitals and healthcare providers, ensuring a steady demand for their enzyme replacement therapies and substrate reduction therapies. Pricing plans are tailored to accommodate various healthcare systems, potentially involving tiered pricing based on volume or patient needs. The company’s flagship products are positioned to provide substantial value in the treatment of lysosomal storage disorders, reflecting the critical nature of these therapies in patient care.Lysosomal Therapeutics plans to further develop and release new product lines targeting lysosomal storage disorders. The company aims to expand its market presence into additional regions in Europe by 2025.00 mn will be utilized to support these product developments and market expansion initiatives.
Who invested in Lysosomal Therapeutics
8 investors across 3 rounds
See all investors in Lysosomal Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Lysosomal Therapeutics
Who invested in Lysosomal Therapeutics?
Lysosomal Therapeutics has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lysosomal Therapeutics raised?
Lysosomal Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Lysosomal Therapeutics last raise money?
Lysosomal Therapeutics's most recent round on record is a Series A, in Jan 2017.
What does Lysosomal Therapeutics do?
Lysosomal Therapeutics is a biotechnology company.
Where is Lysosomal Therapeutics headquartered?
Lysosomal Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like Lysosomal Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Lysosomal Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Lysosomal Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.